MedQuímica Indústria Farmacêutica, with a manufacturing site in the Industrial District of Juiz de Fora, has been operating for 47 years. In 2015, it became part of the Lupin Group, a globally renowned pharmaceutical company, 3rd largest generic company in the United States by prescriptions and 7th largest generic company in India. In Brazil, Lupin’s Medquímica develops an extensive line of solid and liquid medicines classified into five lines: OTC (Over-the-counter Medicines), Branded Generics, Hospital, Generics and Food Supplements. Certified by Anvisa with the Certificate of Good Manufacturing Practices and present throughout the country, the company has penetrated the Brazilian medicines market and touched the lives of millions of people every day.
About Lupin
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions. The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 7.9% of its revenue in research and development in FY23. Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector. For more information, visit www.lupin.com